Anti-hyperglycemic and Anti-lipidemic activities of Diabac (a polyherbal formulation) in Streptozotocin-nicotinamide induced type 2 diabetic rats

Aim: The objective of the work was to investigate the antidiabetic activity of Diabac (a polyherbal formulation) in streptozotocin-nicotinamide induced type 2 diabetic rats. Methods: Oral glucose tolerance test (OGTT) was performed to evaluate effect of Diabac on elevated glucose level. The type 2 diabetes was induced by overnight fasted rats by a single intraperitoneal (i.p.) injection of 65 mg/kg streptozotocin, 15 min. after the i.p. administration of 110 mg/kg nicotinamide. The diabetic rats were treated with Diabac (250, 500 and 1000 mg/kg, p.o.) or glibenclamide (5 mg/kg, p.o) for four week. Various parameters were studied such as fasting blood sugar level, serum insulin levels, glycated hemoglobin (HbA_1C), serum lipid levels, se rum creatinine, urea, uric acid and liver glycogen. Results: Treatment with Diabac significantly reduced the blood sugar levels in OGTT. Diabetic rats showed a significant increase in the levels of glycated hemoglobin, serum lipids, serum creatinine, urea and uric acid, whereas there was a decrease in serum insulin, liver glycogen and HDL-C levels as compared to normal control rats. The administration of Diabac or glibenclamide significantly decreased the levels of glycated hemoglobin, TG, TC, LDL-C, serum creatinine, urea and uric acid, whereas there was an increase in the levels of liver glycogen and HDL-C as compared to diabetic control rats. However, the treatment with Diabac did not show any significant change in serum insulin levels as compared to diabetic control rats. Conclusion: These results of present study concluded that Diabac has anti-diabetic and anti-lipidemic activities which are responsible for its use in traditional medicine.